In vivo imaging of 99mTc-Glucarate-labeled acute necrotic myocardium using microSPECT/CT
Author:
  • Article
  • | |
  • Metrics
  • |
  • Reference [17]
  • |
  • Related
  • |
  • Cited by
  • | |
  • Comments
    Abstract:

    Objective To evaluate the anatomic localization and size of acute necrotic myocardium in the ischemic-reperfused rat hearts using 99mTC-Glucarate and microSPECT/CT. Methods The ischemic-reperfused (IR) rat heart models were established by ligating left anterior descending coronary artery for 60 min. 99mTC-Glucarate was intravenously injected into the rats 24 hours after IR operations. Images were acquired 30 min after administration of 99mTC-Glucarate using microSPECT/CT. Anatomic localization and size of acute necrotic myocardium were analyzed with microSPECT/CT imaging,and these results were compared to those determined by triphenyltetrazolium chloride (TTC) staining. Results The microSPECT/CT images showed hot spot accumulations of 99mTC-Glucarate in IR hearts (the heart-to-liver ratio was 1.90±0.33), not in controls (P < 0.05). The anatomic localization of 99mTC-Glucarate-labeled necrotic myocardium were in correspondence with TTC staining results. The hot spot size was related significantly to necrotic myocardial size determined by TTC staining (R2=0.964). Conclusions The localization and size of acute necrotic myocardium can be assessed by non-invasive microSPECT/CT imaging with 99mTc-Glucarate.

    Reference
    [1] Orlandi C, Crane PD, Edwards DS, et al. Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid[J]. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 1991, 32(2):263-268.
    [2] Khaw BA, Nakazawa A, O'Donnell SM, et al. Avidity of technetium 99m glucarate for the necrotic myocardium: in vivo and in vitro assessment[J]. Journal of nuclear cardiology: official publication of the American Society of Nuclear Cardiology 1997, 4(4):283-290.
    [3] Narula J, Petrov A, Pak KY, et al. Very early noninvasive detection of acute experimental nonreperfused myocardial infarction with 99mTc-labeled glucarate[J]. Circulation 1997, 95(6):1577-1584.
    [4] Arteaga de Murphy C, Ferro-Flores G, Villanueva-Sanchez O, et al. 99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats[J]. International journal of pharmaceutics 2002, 233(1-2):29-34.
    [5] Mariani G, Villa G, Rossettin PF, et al. Detection of acute myocardial infarction by 99mTc-labeled D-glucaric acid imaging in patients with acute chest pain[J]. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 1999, 40(11):1832-1839.
    [6] Wyffels L, Gray BD, Barber C, et al. Detection of myocardial ischemia-reperfusion injury using a fluorescent near-infrared zinc(II)-dipicolyla mine probe and 99mTc glucarate[J]. Molecular imaging 2012, 11(3):187-196.
    [7] Okada DR, Liu Z, Johnson G, et al. 99mTc-glucarate kinetics differentiate normal, stunned, hibernating, and nonviable myocardium in a perfused rat heart model[J]. European journal of nuclear medicine and molecular imaging 2010, 37(10):1909-1917.
    [8] Liu Z, Barrett HH, Stevenson GD, et al. High-resolution imaging with (99m)Tc-glucarate for assessing myocardial injury in rat heart models exposed to different durations of ischemia with reperfusion[J]. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2004, 45(7):1251-1259.
    [9] Ohtani H, Callahan RJ, Khaw BA, et al. Comparison of technetium-99m-glucarate and thallium-201 for the identification of acute myocardial infarction in rats[J]. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 1992, 33(11):1988-1993.
    [10] Khaw BA. The current role of infarct avid imaging[J]. Se minars in nuclear medicine 1999, 29(3):259-270.
    [11] Johnson G, 3rd, Okada CC, Hocherman SD, et al. (99m)Tc-glucarate imaging for the early detection of infarct in partially reperfused canine myocardium[J]. European journal of nuclear medicine and molecular imaging 2006, 33(3):319-328.
    [12] Strauss HW. Myocardial perfusion imaging: perspectives from a turbulent twenty-five years[J]. The quarterly journal of nuclear medicine: official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) 1996, 40(1):20-26.
    [13] Gerson MC, McGoron AJ. Technetium 99m glucarate: what will be its clinical role?[J]. Journal of nuclear cardiology: official publication of the American Society of Nuclear Cardiology 1997, 4(4):336-340.
    [14] Perek N, Sabido O, Le Jeune N, et al. Could 99mTc-glucarate be used to evaluate tumour necrosis? In vitro and in vivo studies in leukaemic tumour cell line U937[J]. European journal of nuclear medicine and molecular imaging 2008, 35(7):1290-1298.
    [15] Gambini JP, Cabral P, Alonso O, et al. Evaluation of 99mTc-glucarate as a breast cancer imaging agent in a xenograft animal model[J]. Nuclear medicine and biology 2011, 38(2):255-260.
    [16] Gambini JP, Nunez M, Cabral P, et al. Evaluation of patients with head and neck cancer by means of 99mTc-glucarate[J]. Journal of nuclear medicine technology 2009, 37(4):229-232.
    [17] Choudhury PS, Savio E, Solanki K, et al. 99mTc Glucarate as a Potential Radiopharmaceutical Agent for Assessment of Tumor Viability: From Bench to the Bed Side[J]. World journal of nuclear medicine 2012, 11(2):47-56.
    Related
    Cited by
Get Citation
Related Videos

Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Revised:May 20,2014
  • Online: August 19,2014
Article QR Code